𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer

✍ Scribed by Marco Volante; Silvia Saviozzi; Ida Rapa; Paolo Ceppi; Susanna Cappia; Raffaele Calogero; Silvia Novello; Piero Borasio; Mauro Papotti; Giorgio V. Scagliotti


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
396 KB
Volume
110
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND.

In recent years, molecular insights shed light on the role of the epidermal growth factor receptor (EGFR) in nonsmall cell lung cancer (NSCLC), and new therapeutic agents, such as the EGFR tyrosine kinase inhibitors, were tested successfully, with responsiveness to those agents more likely in those patients with specific EGFR gene alterations. The objective of the current study was to investigate the protein profiles of EGFR, c‐erb‐B2, transforming growth factor α (TGF‐α) (one of the EGFR ligands commonly expressed in NSCLC), and some downstream molecules, potentially to detect a subset of tumors with an activated autocrine loop that is responsible for higher intracellular signaling.

METHODS.

One hundred twelve consecutive patients with resected NSCLC were analyzed by immunohistochemistry for EGFR, the c‐erb‐B2 receptor, TGF‐α, and pivotal molecules downstream from EGFR activation. Statistical correlations between the investigated molecular expression profiles and clinicopathologic data were performed.

RESULTS.

EGFR, c‐erb‐B2, TGF‐α and downstream molecule expression, per se, was not correlated significantly with any clinicopathologic variables, with the exception of a significant correlation between squamous histology and EGFR and between adenocarcinoma and TGF‐α. However, nearly 30% of NSCLCs demonstrated coexpression of both TGF‐α and EGFR, and this molecular status was associated positively with a statistically significant expression of phosphatidylinositol 3 kinase and an inversely with mitogen‐activated protein kinase expression.

CONCLUSIONS.

The presence of a subgroup of NSCLCs with an activated autocrine loop may help to explain the mechanisms that lead to the relative ineffectiveness of the EGFR tyrosine kinase inhibitor and may support new clinical trials to define whether the subgroup of patients with these tumors reasonably may benefit from higher doses of such inhibitors or from the simultaneous inhibition of EGFR downstream signaling targets. Cancer 2007. © 2007 American Cancer Society.


📜 SIMILAR VOLUMES


Epidermal growth factor receptor mutatio
✍ Victor Cohen; Jason S. Agulnik; Celina Ang; Goulnar Kasymjanova; Gerald Batist; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 1 views

## Abstract ## BACKGROUND: Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) in patients with nonsmall cell lung cancer (NSCLC). ## METHODS: The authors tested the possibility that nucleoti

Cooperative interaction between protein
✍ Amy Kluge; Snehal Dabir; Jeffrey Kern; David Nethery; Balazs Halmos; Patrick Ma; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 377 KB

## Abstract Epidermal Growth Factor Receptor (EGFR) targeting in nonsmall cell lung cancer (NSCLC) is an established treatment modality; however, it only benefits a minority of patients. STAT3 (signal transducer and activator of transcription‐3) plays an important role in the oncogenic signal trans

Angiotensin II activates extracellular s
✍ S. Greco; A. Muscella; M.G. Elia; P. Salvatore; C. Storelli; A. Mazzotta; C. Man 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB 👁 2 views

## Abstract Angiotensin II (Ang II) induces, through AT1, intracellular Ca^2+^ increase in both normal and cancerous breast cells in primary culture (Greco et al., 2002 Cell Calcium 2:1–10). We here show that Ang II stimulated, in a dose‐dependent manner, the 24 h‐proliferation of breast cancer cel